These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 34193864)

  • 41. Facing the Challenges in the COVID-19 Pandemic Era: From Standard Treatments to the Umbilical Cord-Derived Mesenchymal Stromal Cells as a New Therapeutic Strategy.
    Russo E; Corrao S; Di Gaudio F; Alberti G; Caprnda M; Kubatka P; Kruzliak P; Miceli V; Conaldi PG; Borlongan CV; La Rocca G
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371134
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy.
    Barros I; Silva A; de Almeida LP; Miranda CO
    Cytokine Growth Factor Rev; 2021 Apr; 58():114-133. PubMed ID: 33397585
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Virology of SARS-CoV-2 and management of nCOVID-19 utilizing immunomodulation properties of human mesenchymal stem cells-a literature review.
    Sachdeva K; Kumar A; Mohanty S
    Stem Cell Investig; 2021; 8():23. PubMed ID: 34917676
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mesenchymal Stem Cell-Based Therapy for COVID-19: Possibility and Potential.
    Xiong J; Bao L; Qi H; Feng Z; Shi Y
    Curr Stem Cell Res Ther; 2021; 16(2):105-108. PubMed ID: 32479246
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Visualized Analyses of Investigations Upon Mesenchymal Stem/stromal Cell-based Cytotherapy and Underlying Mechanisms for COVID-19 Associated ARDS.
    Aitong W; Leisheng Z; Hao Y
    Curr Stem Cell Res Ther; 2022; 17(1):2-12. PubMed ID: 34254927
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bone Marrow Mesenchymal Stem Cell-Derived Extracellular Vesicle Infusion for the Treatment of Respiratory Failure From COVID-19: A Randomized, Placebo-Controlled Dosing Clinical Trial.
    Lightner AL; Sengupta V; Qian S; Ransom JT; Suzuki S; Park DJ; Melson TI; Williams BP; Walsh JJ; Awili M
    Chest; 2023 Dec; 164(6):1444-1453. PubMed ID: 37356708
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial.
    Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; McAuley DF; O'Kane C
    Trials; 2022 May; 23(1):401. PubMed ID: 35562778
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravenous Administration of Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSC) for Acute Respiratory Distress Syndrome Due to COVID-19 Infection.
    Perez JA; Parcero Valdes JJ; Corral Moreno R; Gomez Cuevas LI; Lopez JJ; Ichim T; McGreevy K; Lin F; Kesari S; Datta S
    Cureus; 2023 Aug; 15(8):e44110. PubMed ID: 37638263
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mesenchymal stromal cell therapy for COVID-19 acute respiratory distress syndrome: a double-blind randomised controlled trial.
    Martínez-Muñoz ME; Payares-Herrera C; Lipperheide I; Malo de Molina R; Salcedo I; Alonso R; Martín-Donaire T; Sánchez R; Zafra R; García-Berciano M; Trisán-Alonso A; Pérez-Torres M; Ramos-Martínez A; Ussetti P; Rubio JJ; Avendaño-Solà C; Duarte RF
    Bone Marrow Transplant; 2024 Jun; 59(6):777-784. PubMed ID: 38409332
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial.
    Monsel A; Hauw-Berlemont C; Mebarki M; Heming N; Mayaux J; Nguekap Tchoumba O; Diehl JL; Demoule A; Annane D; Marois C; Demeret S; Weiss E; Voiriot G; Fartoukh M; Constantin JM; Mégarbane B; Plantefève G; Malard-Castagnet S; Burrel S; Rosenzwajg M; Tchitchek N; Boucher-Pillet H; Churlaud G; Cras A; Maheux C; Pezzana C; Diallo MH; Ropers J; Menasché P; Larghero J;
    Crit Care; 2022 Feb; 26(1):48. PubMed ID: 35189925
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Potential therapeutic effects and nano-based delivery systems of mesenchymal stem cells and their isolated exosomes to alleviate acute respiratory distress syndrome caused by COVID-19.
    Ghiasi M; Kheirandish Zarandi P; Dayani A; Salimi A; Shokri E
    Regen Ther; 2024 Dec; 27():319-328. PubMed ID: 38650667
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mesenchymal stem cells as living anti-inflammatory therapy for COVID-19 related acute respiratory distress syndrome.
    Lin F; Ichim TE; Pingle S; Jones LD; Kesari S; Ashili S
    World J Stem Cells; 2020 Oct; 12(10):1067-1079. PubMed ID: 33178392
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential.
    Gorman E; Millar J; McAuley D; O'Kane C
    Expert Rev Respir Med; 2021 Mar; 15(3):301-324. PubMed ID: 33172313
    [No Abstract]   [Full Text] [Related]  

  • 54. Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm.
    Song N; Wakimoto H; Rossignoli F; Bhere D; Ciccocioppo R; Chen KS; Khalsa JK; Mastrolia I; Samarelli AV; Dominici M; Shah K
    Stem Cells; 2021 Jun; 39(6):707-722. PubMed ID: 33586320
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019.
    Canham MA; Campbell JDM; Mountford JC
    J Transl Med; 2020 Sep; 18(1):359. PubMed ID: 32958009
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mechanisms of Potential Therapeutic Utilization of Mesenchymal Stem Cells in COVID-19 Treatment.
    Fang Y; Lao P; Tang L; Chen J; Chen Y; Sun L; Tan W; Fan X
    Cell Transplant; 2023; 32():9636897231184611. PubMed ID: 37395459
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mesenchymal stromal/stem cells (MSCs) and MSC-derived extracellular vesicles in COVID-19-induced ARDS: Mechanisms of action, research progress, challenges, and opportunities.
    Moradinasab S; Pourbagheri-Sigaroodi A; Zafari P; Ghaffari SH; Bashash D
    Int Immunopharmacol; 2021 Aug; 97():107694. PubMed ID: 33932694
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical progress in MSC-based therapies for the management of severe COVID-19.
    Rossello-Gelabert M; Gonzalez-Pujana A; Igartua M; Santos-Vizcaino E; Hernandez RM
    Cytokine Growth Factor Rev; 2022 Dec; 68():25-36. PubMed ID: 35843774
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome.
    Harrell CR; Jovicic BP; Djonov V; Volarevic V
    Anal Cell Pathol (Amst); 2020; 2020():1939768. PubMed ID: 33274176
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.